Ting‐Ying Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ting‐Ying Huang has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Sengwee Toh
Harvard Pilgrim Health Care Institute Department of Population Medicine Boston, MA 02215
3 shared publications James Marshall
Department of Population Medicine Harvard Pilgrim Health Care Institute Boston Massachusetts USA
2 shared publications- Judith C. Maro
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute , Boston, MA
2 shared publications Aaron B Mendelsohn
Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA
1 shared publicationAbby Anderson
Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
1 shared publicationAlecia Clary
Evidence to Practice Durham North Carolina USA
1 shared publication
Latest Publications
- 9 February 2026
- Published by Wiley in Diabetic Medicine
- Vol. 43 (4) , e70208
Post‐authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population
Aims: To evaluate diabetic ketoacidosis (DKA) risk among new users of ertugliflozin versus sulfonylureas (SU) or thiazolidinediones (TZD) and incretin‐based drugs in patients with type 2 diabetes. Methods: We used Medicare and Medicaid fee‐for‐service adjudicated claims within the Innovation in Medical Evidence and Development Surveillance network to identify three new‐user cohorts: (1) ertugliflozin; (2) SU/TZD; and (3) incretin‐based drugs. The outcome was a principal hospital discharge diagnosis for DKA. Adjusted hazard ratios (HRs) were estimated after 1:1 propensity score (PS) matching, separately for ertugliflozin vs. SU/TZD and vs. incretin‐based drugs. Subgroup analyses were performed based on baseline insulin use. Results: After PS matching, baseline characteristics were similarly distributed in each cohort. For ertugliflozin ( n = 42,907) vs. SU/TZD ( n = 42,907), the incidence rates of DKA per 1000 person‐years (PY) were 2.95 and 1.49, respectively. For ertugliflozin ( n = 42,247) vs. incretin‐based drugs ( n = 42,247), the incidence rates of DKA per 1000 PY were 2.76 and 1.06, respectively. For ertugliflozin vs. SU/TZD, the HR [95% confidence interval (CI)] was 1.88 [1.17–3.02]; in non‐insulin users, 2.34 [1.27–4.31]; and in insulin users, 1.17 [0.54–2.52]. For ertugliflozin vs. incretin‐based drugs, the HR [95% CI] was 2.40 [1.40–4.11]; in non‐insulin users, 2.84 [1.42–5.66]; and in insulin users, 1.87 [0.79–4.46]. Conclusions: Ertugliflozin was associated with a higher risk of DKA relative to comparators. HRs were higher among new users with no‐concomitant insulin use than those with concomitant insulin use. Results were consistent with prior SGLT2i data and highlighted the importance of caution by both patients and physicians.
- 9 February 2026
- Published by Wiley in Diabetic Medicine
- Vol. 43 (4) , e70208
Post‐authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population
Aims: To evaluate diabetic ketoacidosis (DKA) risk among new users of ertugliflozin versus sulfonylureas (SU) or thiazolidinediones (TZD) and incretin‐based drugs in patients with type 2 diabetes. Methods: We used Medicare and Medicaid fee‐for‐service adjudicated claims within the Innovation in Medical Evidence and Development Surveillance network to identify three new‐user cohorts: (1) ertugliflozin; (2) SU/TZD; and (3) incretin‐based drugs. The outcome was a principal hospital discharge diagnosis for DKA. Adjusted hazard ratios (HRs) were estimated after 1:1 propensity score (PS) matching, separately for ertugliflozin vs. SU/TZD and vs. incretin‐based drugs. Subgroup analyses were performed based on baseline insulin use. Results: After PS matching, baseline characteristics were similarly distributed in each cohort. For ertugliflozin ( n = 42,907) vs. SU/TZD ( n = 42,907), the incidence rates of DKA per 1000 person‐years (PY) were 2.95 and 1.49, respectively. For ertugliflozin ( n = 42,247) vs. incretin‐based drugs ( n = 42,247), the incidence rates of DKA per 1000 PY were 2.76 and 1.06, respectively. For ertugliflozin vs. SU/TZD, the HR [95% confidence interval (CI)] was 1.88 [1.17–3.02]; in non‐insulin users, 2.34 [1.27–4.31]; and in insulin users, 1.17 [0.54–2.52]. For ertugliflozin vs. incretin‐based drugs, the HR [95% CI] was 2.40 [1.40–4.11]; in non‐insulin users, 2.84 [1.42–5.66]; and in insulin users, 1.87 [0.79–4.46]. Conclusions: Ertugliflozin was associated with a higher risk of DKA relative to comparators. HRs were higher among new users with no‐concomitant insulin use than those with concomitant insulin use. Results were consistent with prior SGLT2i data and highlighted the importance of caution by both patients and physicians.
- 18 July 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 114 (4) , 815-824
Six Years of the US Food and Drug Administration's Postmarket Active Risk Identification and Analysis System in the Sentinel Initiative: Implications for Real World Evidence Generation
Congress mandated the creation of a postmarket Active Risk Identification and Analysis (ARIA) system containing data on 100 million individuals for monitoring risks associated with drug and biologic products using data from disparate sources to complement the US Food and Drug Administration's (FDA's) existing postmarket capabilities. We report on the first 6 years of ARIA utilization in the Sentinel System (2016–2021). The FDA has used the ARIA system to evaluate 133 safety concerns; 54 of these evaluations have closed with regulatory determinations, whereas the rest remain in progress. If the ARIA system and the FDA's Adverse Event Reporting System are deemed insufficient to address a safety concern, then the FDA may issue a postmarket requirement to a product's manufacturer. One hundred ninety‐seven ARIA insufficiency determinations have been made. The most common situation for which ARIA was found to be insufficient is the evaluation of adverse pregnancy and fetal outcomes following in utero drug exposure, followed by neoplasms and death. ARIA was most likely to be sufficient for thromboembolic events, which have high positive predictive value in claims data alone and do not require supplemental clinical data. The lessons learned from this experience illustrate the continued challenges using administrative claims data, especially to define novel clinical outcomes. This analysis can help to identify where more granular clinical data are needed to fill gaps to improve the use of real‐world data for drug safety analyses and provide insights into what is needed to efficiently generate high‐quality real‐world evidence for efficacy.
- 18 July 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 114 (4) , 815-824
Six Years of the US Food and Drug Administration's Postmarket Active Risk Identification and Analysis System in the Sentinel Initiative: Implications for Real World Evidence Generation
Congress mandated the creation of a postmarket Active Risk Identification and Analysis (ARIA) system containing data on 100 million individuals for monitoring risks associated with drug and biologic products using data from disparate sources to complement the US Food and Drug Administration's (FDA's) existing postmarket capabilities. We report on the first 6 years of ARIA utilization in the Sentinel System (2016–2021). The FDA has used the ARIA system to evaluate 133 safety concerns; 54 of these evaluations have closed with regulatory determinations, whereas the rest remain in progress. If the ARIA system and the FDA's Adverse Event Reporting System are deemed insufficient to address a safety concern, then the FDA may issue a postmarket requirement to a product's manufacturer. One hundred ninety‐seven ARIA insufficiency determinations have been made. The most common situation for which ARIA was found to be insufficient is the evaluation of adverse pregnancy and fetal outcomes following in utero drug exposure, followed by neoplasms and death. ARIA was most likely to be sufficient for thromboembolic events, which have high positive predictive value in claims data alone and do not require supplemental clinical data. The lessons learned from this experience illustrate the continued challenges using administrative claims data, especially to define novel clinical outcomes. This analysis can help to identify where more granular clinical data are needed to fill gaps to improve the use of real‐world data for drug safety analyses and provide insights into what is needed to efficiently generate high‐quality real‐world evidence for efficacy.
- Open Access
- 19 December 2022
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 10 (6) , e002916
Using the IMEDS distributed database for epidemiological studies in type 2 diabetes mellitus
Introduction: This study aimed to assess data relevancy and data quality of the Innovation in Medical Evidence Development and Surveillance System Distributed Database (IMEDS-DD) for diabetes research and to evaluate comparability of its type 2 diabetes cohort to the general type 2 diabetes population. Research design and methods: A retrospective study was conducted using the IMEDS-DD. Eligible members were adults with a medical encounter between April 1, 2018 and March 31, 2019 (index period). Type 2 diabetes and co-existing conditions were determined using all data available from April 1, 2016 to the most recent encounter within the index period. Type 2 diabetes patient characteristics, comorbidities and hemoglobin A1c (HbA1c) values were summarized and compared with those reported in national benchmarks and literature. Results: Type 2 diabetes prevalence was 12.6% in the IMEDS-DD. Of 4 14 672 patients with type 2 diabetes, 52.8% were male, and the mean age was 65.0 (SD 13.3) years. Common comorbidities included hypertension (84.5%), hyperlipidemia (82.8%), obesity (45.3%), and cardiovascular disease (44.7%). Moderate-to-severe chronic kidney disease was observed in 20.2% patients. The most commonly used antihyperglycemic agents included metformin (35.7%), sulfonylureas (14.8%), and insulin (9.9%). Less than one-half (48.9%) had an HbA1c value recorded. These findings demonstrated the notable similarity in patient characteristics between type 2 diabetes populations identified within the IMEDS-DD and other large databases. Conclusions: Despite the limitations related to HbA1c data, our findings indicate that the IMEDS-DD contains robust information on key data elements to conduct pharmacoepidemiological studies in diabetes, including member demographic and clinical characteristics and health services utilization.
- 19 December 2022
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 10 (6) , e002916
Open AccessUsing the IMEDS distributed database for epidemiological studies in type 2 diabetes mellitus
Introduction: This study aimed to assess data relevancy and data quality of the Innovation in Medical Evidence Development and Surveillance System Distributed Database (IMEDS-DD) for diabetes research and to evaluate comparability of its type 2 diabetes cohort to the general type 2 diabetes population. Research design and methods: A retrospective study was conducted using the IMEDS-DD. Eligible members were adults with a medical encounter between April 1, 2018 and March 31, 2019 (index period). Type 2 diabetes and co-existing conditions were determined using all data available from April 1, 2016 to the most recent encounter within the index period. Type 2 diabetes patient characteristics, comorbidities and hemoglobin A1c (HbA1c) values were summarized and compared with those reported in national benchmarks and literature. Results: Type 2 diabetes prevalence was 12.6% in the IMEDS-DD. Of 4 14 672 patients with type 2 diabetes, 52.8% were male, and the mean age was 65.0 (SD 13.3) years. Common comorbidities included hypertension (84.5%), hyperlipidemia (82.8%), obesity (45.3%), and cardiovascular disease (44.7%). Moderate-to-severe chronic kidney disease was observed in 20.2% patients. The most commonly used antihyperglycemic agents included metformin (35.7%), sulfonylureas (14.8%), and insulin (9.9%). Less than one-half (48.9%) had an HbA1c value recorded. These findings demonstrated the notable similarity in patient characteristics between type 2 diabetes populations identified within the IMEDS-DD and other large databases. Conclusions: Despite the limitations related to HbA1c data, our findings indicate that the IMEDS-DD contains robust information on key data elements to conduct pharmacoepidemiological studies in diabetes, including member demographic and clinical characteristics and health services utilization.
- 1 January 2022
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 226 (1) , 140-143
Incidence of severe uterine bleeding outcomes among oral anticoagulant users and nonusers
- 1 January 2022
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 226 (1) , 140-143
Incidence of severe uterine bleeding outcomes among oral anticoagulant users and nonusers
- 20 October 2019
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 107 (4) , 966-977
Reproducing Protocol‐Based Studies Using Parameterizable Tools—Comparison of Analytic Approaches Used by Two Medical Product Surveillance Networks
The US Sentinel System and the Canadian Network for Observational Drug Effect Studies (CNODES) are two medical product safety surveillance networks. Using Sentinel's preprogrammed, parameterizable analytic tools, we reproduced two protocol‐based studies conducted by CNODES to assess the risks of acute pancreatitis and heart failure (HF) associated with the use of incretin‐based drugs, compared with use of ≥ 2 oral hypoglycemic agents. Results from the replication new‐user cohort analyses aligned with those from the CNODES nested case‐control studies. The adjusted hazard ratios were 0.95 (0.81–1.12; vs. 1.03 (0.87–1.22) in CNODES) for acute pancreatitis and 0.91 (0.84–1.00; vs. 0.82 (0.67–1.00) in CNODES) for HF among patients without HF history. The CNODES's common protocol approach allows studies tailored to specific safety questions, whereas the Sentinel's common data model plus pretested program approach enables more rapid analysis. Despite these differences, it is possible to obtain comparable results using both approaches.
- 20 October 2019
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 107 (4) , 966-977
Reproducing Protocol‐Based Studies Using Parameterizable Tools—Comparison of Analytic Approaches Used by Two Medical Product Surveillance Networks
The US Sentinel System and the Canadian Network for Observational Drug Effect Studies (CNODES) are two medical product safety surveillance networks. Using Sentinel's preprogrammed, parameterizable analytic tools, we reproduced two protocol‐based studies conducted by CNODES to assess the risks of acute pancreatitis and heart failure (HF) associated with the use of incretin‐based drugs, compared with use of ≥ 2 oral hypoglycemic agents. Results from the replication new‐user cohort analyses aligned with those from the CNODES nested case‐control studies. The adjusted hazard ratios were 0.95 (0.81–1.12; vs. 1.03 (0.87–1.22) in CNODES) for acute pancreatitis and 0.91 (0.84–1.00; vs. 0.82 (0.67–1.00) in CNODES) for HF among patients without HF history. The CNODES's common protocol approach allows studies tailored to specific safety questions, whereas the Sentinel's common data model plus pretested program approach enables more rapid analysis. Despite these differences, it is possible to obtain comparable results using both approaches.